|View printer-friendly version|
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
During the fourth quarter of 2019,
“We are thrilled to announce a new clinical collaboration to explore our SB 11285 IV
As noted above, Phase 1a of the IV SB 11285 Phase 1 trial is a dose-escalation study with monotherapy followed by combination with one or more checkpoint inhibitors and is designed to determine a recommended Phase 2 dose. Phase 1b of the trial will explore IV SB 11285 antitumor activity in combination with a checkpoint inhibitor in selected tumor types. The trial is being conducted at multiple sites in the United States.
About Spring Bank Pharmaceuticals
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.